SCOPE 2 - Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography.

Chemoradiotherapy Esophageal Neoplasms / diagnostic imaging Humans Positron Emission Tomography Computed Tomography
Dose escalation oesophageal radiotherapy systemic therapy personalisation

Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
07 2022
Historique:
received: 12 10 2021
revised: 01 03 2022
accepted: 23 03 2022
pubmed: 26 4 2022
medline: 16 6 2022
entrez: 25 4 2022
Statut: ppublish

Résumé

The SCOPE 2 trial of definitive chemoradiotherapy in oesophageal cancer investigates the benefits of radiotherapy dose escalation and systemic therapy optimisation. The trial opened in 2016. The landscape of oesophageal cancer treatment over the lifetime of this trial has changed significantly and the protocol has evolved to reflect this. However, with the recent results of the Dutch phase III ART DECO study showing no improvement in local control or overall survival with radiotherapy dose escalation in a similar patient group, we sought to determine if the SCOPE 2 trial is still answering the key unanswered questions for oesophageal radiotherapy. Here we discuss the rationale behind the SCOPE 2 trial, outline the trial schema and review current data on dose escalation and outline recommendations for future areas of research.

Identifiants

DOI: 10.1016/j.clon.2022.03.019 PMID: 35466013
pubmed: 35466013
pii: S0936-6555(22)00170-4
doi: 10.1016/j.clon.2022.03.019
pii:
doi:

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e269-e280

Subventions

Organisme : Cancer Research UK
ID : A17606
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Auteurs

S Bridges (S)

Centre for Trials Research, Cardiff University, Cardiff, UK.

B Thomas (B)

Velindre University NHS Trust, Cardiff, UK. Electronic address: betsan.thomas@wales.nhs.uk.

G Radhakrishna (G)

The Christie NHS Foundation Trust, Manchester, UK.

M Hawkins (M)

University College London, Medical Physics and Biomedical Engineering, London, UK.

A Holborow (A)

South West Wales Cancer Centre, Swansea, UK.

C Hurt (C)

Centre for Trials Research, Cardiff University, Cardiff, UK.

S Mukherjee (S)

Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.

L Nixon (L)

Centre for Trials Research, Cardiff University, Cardiff, UK.

T Crosby (T)

Velindre University NHS Trust, Cardiff, UK.

S Gwynne (S)

South West Wales Cancer Centre, Swansea, UK; Swansea University Medical School, Swansea, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Radiothérapie › Chimioradiothérapie › SCOPE 2 - Still Answering the Unanswered...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › Tumeurs de l'oesophage › SCOPE 2 - Still Answering the Unanswered...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › SCOPE 2 - Still Answering the Unanswered...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › SCOPE 2 - Still Answering the Unanswered...